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1. Introduction 
Solid tumors comprise not only cancer cells but also host stromal cells, such as vascular 
cells, inflammatory/immune cells, and cancer-associated fibroblasts. The crosstalk between 
cancer cells and stromal cells plays an important role in tumor growth, metastasis, and 
response to antitumor therapy (Hanahan and Weinberg, 2011; Joyce and Pollard, 2009; 
Petrulio et al., 2006). Cancer cells with oncogenic mutations are central to tumor formation. 
Endothelial cells in tumors form new blood vessels (angiogenesis) which bring oxygen and 
nutrients to the growing tumor (Ferrara and Kerbel, 2005), and also regulate leukocyte 
infiltration and tumor cell metastasis (Chouaib et al., 2010). Inflammatory cells have both 
tumor-promoting and tumor-preventing effects (Grivennikov et al., 2010; Hanahan and 
Weinberg, 2011). Fibroblasts are the most abundant cells in the tumor stroma and have been 
demonstrated to have tumor-promoting activities (Bhowmick et al., 2004). Moreover, cancer 
cells within tumors are heterogeneous and composed of distinct subpopulations with 
different states of tumorigenicity. One subpopulation of cells that has recently been 
extensively studied is the cancer initiating cell or cancer stem cell (CSC) (Cho and Clarke, 
2008), which exhibits high capacity of generating new tumors.  
The microenvironment in solid tumors is very distinct from that in normal tissues. Due to 
deregulated cancer cell metabolism, highly heterogeneous vasculature and defective blood 
perfusion, the tumor microenvironment is characterized by hypoxia and acidosis (Cairns et 
al., 2006; Gatenby et al., 2006; Gatenby and Gillies, 2004). The uncontrolled proliferation of 
tumor cells results in a growing mass that rapidly consumes oxygen, glucose and nutrients 
(Gatenby and Gillies, 2004).  When an oxygen diffusion limit is reached, some regions of a 
tumor become hypoxic. Cancer cells rely heavily upon glycolysis (‘Warburg effect’) to 
generate ATP and metabolic intermediates for biosynthesis (Gatenby and Gillies, 2004; 
Vander Heiden et al., 2009). There is much evidence to link the connection between the 
adaptation to hypoxia and the development of an aggressive tumor phenotype in both 
experimental and clinical settings (Chang et al., 2011; Gatenby and Gillies, 2004). In addition 
to hypoxia, the existence of acidosis is a defining hallmark of the tumor microenvironment. 
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This condition arises mainly due to an increase in the production of lactic acid by glycolysis 
along with other proton sources (Gatenby and Gillies, 2004; Helmlinger et al., 2002; 
Yamagata et al., 1998). Acidosis is a selection force for cancer cell somatic evolution, 
modulates cancer cell invasion and metastasis, and affects the efficacy of some 
chemotherapeutic drugs (Cairns et al., 2006; Gatenby et al., 2006; Gatenby and Gillies, 2004).  
Here we will describe cellular heterogeneity, hypoxia, and acidosis in the tumor 
microenvironment, and discuss some recent progresses in targeting tumor angiogenesis, 
inflammation, hypoxia and acidosis-related pathways for cancer prevention and therapy.    
2. Tumor microenvironments and cancer progression 
2.1 Complex cellular components in solid tumors 
Tumor is an aberrantly proliferating tissue that contains cancerous cells and host stromal 
cells such as vascular cells, inflammatory cells, and fibroblasts. These cells are crucial for 
cancer initiation, progression and metastasis and have been exploited as targets for cancer 
therapy and prevention (Ferrara and Kerbel, 2005; Fukumura and Jain, 2007; Hanahan and 
Weinberg, 2011).  
2.1.1 Vascular cells 
Tumor blood vessels, like normal vessels, are composed of endothelial cells, 
pericytes/smooth muscle cells and basement membrane. However, all of these components 
are morphologically and/or functionally different from the normal counterparts (Baluk et 
al., 2005). 
Tumor-associated endothelial cells (TECs) are the major player in the formation of tumor 
vasculature through sprouting from pre-existing blood vessels (a process called 
‘angiogenesis’). During blood vessel formation, endothelial cells proliferate, migrate and 
form the inner layer of a lumen, followed by basement membrane formation and pericyte 
attachment. Angiogenesis is stimulated by excessive pro-angiogenic factors secreted by 
tumor cells or stromal cells in an oxygen-depleted microenvironment. Moreover, bone 
marrow-derived endothelial progenitor cells recruited to tumor stroma can contribute to 
blood vessel construction by incorporating into vessels (Lyden et al., 2001). New blood 
vessel formation is critical for tumor development and progression, as it delivers nutrients 
and oxygen to growing tumor and removes metabolic wastes. In addition, vascular 
endothelial cells form a barrier between circulating blood cells, tumor cells and the 
extracellular matrix (ECM), thus playing a central role in regulating the trafficking of 
leukocytes and tumor cells (Chouaib et al., 2010). In this regard, endothelial cells are critical 
for boosting a host immune defense against cancer cells and for controlling tumor 
metastasis. However, the ‘gate-keeping’ function of endothelial cells in tumors is heavily 
compromised. TECs are not tightly associated with each other, resulting in wider inter-
endothelial junctions that cause plasma leakage and hemorrhage (Hashizume et al., 2000). 
Consequently, tumor vasculature is often leaky and less efficient in blood perfusion, leading 
to high interstitial fluid pressure, hypoxia and acidic extracellular pH that significantly 
affect the delivery and efficacy of chemotherapeutic drugs. The leaky blood vessels also 
facilitate the intravastion of tumor cells and promote tumor metastasis. 
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TECs are different from endothelial cells in normal tissues at several aspects. It has been 
reported that human hepatocellular carcinoma-derived endothelial cells, when compared to 
the ones from adjacent normal liver tissue, show increased apoptosis resistance, enhanced 
angiogenic activity and acquire more resistance to the combination of angiogenesis inhibitor 
with chemotherapeutic drugs (Xiong et al., 2009). Studies have also revealed distinct gene 
expression profiles of TECs and identified cell-surface markers distinguishing tumor versus 
normal endothelial cells (Seaman et al., 2007).  
In blood vessels, pericytes are smooth muscle cell-like cells that cover the vascular tube. 
They are intimately associated with endothelial cells and embedded within the vascular 
basement membrane, and play an important role in the maintenance of blood vessel 
integrity. Pericytes in tumors are different from normal ones: in tumors, pericytes are often 
less abundant and more loosely attached to the endothelial layer (Abramsson et al., 2002; 
Morikawa et al., 2002). The abnormality in pericytes weakens the vessel wall and increases 
vessel leakiness. Pericytes express several markers, though none is pericyte-exclusive, 
including ǂ-smooth muscle actin (ǂSMA), platelet-derived growth factor receptor-ǃ 
(PDGFR-ǃ) and NG2 (Gerhardt and Betsholtz, 2003; McDonald and Choyke, 2003). PDGF-B 
signaling is important for pericyte recruitment and attachment to endothelial cells during 
vascular development (Abramsson et al., 2002; Abramsson et al., 2003).  
2.1.2 Inflammatory/immune cells 
Tumors are often infiltrated by inflammatory cells, such as macrophages, neutrophils, 
lymphocytes, mast cells, and myeloid progenitors. This phenomenon was initially observed 
by Rudolf Virchow more than a century ago and thought as an immunological response 
attempting to eliminate cancer cells. Whereas immune cells play a role in recognizing and 
eradicating early cancer cells (Kim et al., 2007), mounting evidence has also shown that 
inflammatory cells within tumors can enhance tumor initiation and progression by helping 
cancer cells acquire hallmark capabilities (Grivennikov et al., 2010; Hanahan and Weinberg, 
2011). Inflammation is considered as an ‘enabling characteristic’ of tumor biology (Hanahan 
and Weinberg, 2011).  
Pathological studies show that the abundance of certain types of infiltrating inflammatory 
cells, such as macrophages, neutrophils and mast cells, is correlated with poor prognosis of 
cancer patients (Murdoch et al., 2008). Tumor associated macrophages (TAMs), along with 
mast cells, neutrophils and other immune cells, produce cytokines (e.g. TNFǂ and IL-1), 
chemokines (e.g. CCL2 and CXCL12), angiogenic factors (e.g. VEGF, PDGF, FGF and IL-8), 
and matrix-degrading enzymes (e.g. MMPs, cathepsin proteases and heparanase) 
(Grivennikov et al., 2010; Karnoub and Weinberg, 2006). Some inflammatory cells, 
particularly neutrophils, also generate reactive oxygen and nitrogen species. These bioactive 
factors promote cancer cell proliferation, invasion and resistance to apoptosis through, for 
instance, the interleukin-JAK/STAT pathway (Ara and Declerck, 2010), and induce new 
blood vessel formation in the tumor. Extracelluar matrix-degrading enzymes promote 
cancer cell invasion and metastasis, whereas accumulation of reactive oxygen and nitrogen 
species can cause DNA mutagenesis, suppress DNA repair enzymes, increase genomic 
instability, and aggravate cancer progression.  
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While the tumor-promoting effects of infiltrating inflammatory cells have been well 
documented, certain types of immune cells, particularly cytotoxic T cells and natural killer 
cells, exhibit anti-tumor activities. The high numbers of these cells within a tumor predict a 
favorable prognosis (de Visser, 2008; Fridman et al., 2011). Immune surveillance is 
considered as an important mechanism to inhibit carcinogenesis and maintain tumor 
dormancy (Kim et al., 2007). Evading immune destruction by downregulating tumor 
antigens, suppressing immune cell function and other means is an emerging hallmark of 
cancer cells and plays important roles in cancer progression and metastasis (Hanahan and 
Weinberg, 2011). With regard to cancer therapy, blockade of CTLA-4 (cytotoxic T 
lymphocyte-associated antigen 4), a negative regulator of T cells, by the monoclonal 
antibody, ipilimumab, improved overall survival in patients with metastatic melanoma 
treated in combination with dacarbazine (Robert et al., 2011a). Moreover, expansion of 
tumor-infiltrating lymphocytes ex vivo and adoptive T-cell transfer immunotherapy led to 
regression of metastatic melanoma and durable responses in patients (Dudley et al., 2002; 
Rosenberg et al., 2011).     
2.1.3 Fibroblasts 
Fibroblasts account for the majority of stromal cells within solid tumors and are the 
principal source of ECM constituents (Chang et al., 2002). Fibroblasts in tumors are termed 
as cancer-associated fibroblasts (CAFs).  
Tumors have been described as wounds that do not heal (Dvorak, 1986). Indeed, it has been 
observed that tumor-associated fibroblasts are biologically similar to the ones involved in 
wound healing or fibrosis (Ryan et al., 1973; Schor et al., 1988). Fibroblasts involved in these 
processes produce more ECM proteins and proliferate faster than the normal counterparts 
from healthy tissues (Castor et al., 1979; Muller and Rodemann, 1991). Fibroblasts with these 
properties are referred as “activated fibroblasts” or “myofibroblasts”, due to their 
characteristic expression of ǂ-smooth muscle actin (ǂ-SMA) (Gabbiani, 2003; Ronnov-Jessen 
et al., 1996). Fibroblasts can be activated by various stimuli, such as transforming growth 
factor-ǃ (TGFǃ), epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and 
fibroblast growth factor 2 (FGF2) (Zeisberg et al., 2000).  
CAFs play an important role in promoting tumor initiation and progression by stimulating 
angiogenesis and tumor cell growth and invasion (Shimoda et al., 2010). The existence of a 
large number of CAFs in tumors is often associated with poor prognosis (Maeshima et al., 
2002; Surowiak et al., 2006). CAFs produce growth factors, cytokines, chemokines and ECM 
proteases to stimulate angiogenesis and cancer cell proliferation and invasion. For example, 
CAFs secrete elevated levels of stromal cell-derived factor 1 (SDF-1; also called CXCL12) 
that facilitates angiogenesis by recruiting endothelial progenitor cells into the tumor (Orimo 
et al., 2005). SDF-1 can also interact with the CXCR4 receptor expressed on the surface of 
cancer cells, thus stimulating  tumor cell growth and promoting tumor progression in vivo 
(Orimo and Weinberg, 2006). TGFǃ, another factor produced by CAFs, is a critical mediator 
of the epithelial-to-mesenchymal transition (EMT); therefore, CAFs might contribute to EMT 
in nearby cancer cells and promote their invasiveness (Shimoda et al., 2010).  Moreover, 
CAFs facilitate cancer cells to invade ECM and metastasize by releasing ECM-degrading 
proteases, such as matrix metalloproteinases (MMPs) (Boire et al., 2005; Sternlicht et al., 
1999).  
www.intechopen.com
 
Targeting Tumor Microenvironments for Cancer Prevention and Therapy 
 
7 
CAFs can maintain the myofibroblastic properties even after several passages in vitro 
without further signaling from carcinoma cells. How do CAFs acquire and maintain their 
activated phenotype? There are some controversial results with regard to the presence of 
somatic genetic alterations in CAFs. It has been reported that stroma microdissected from 
various human cancers exhibited some genetic alterations, such as chromosomal loss of 
heterozygosity (LOH) and somatic mutations (Currie et al., 2007; Kurose et al., 2002; 
Moinfar et al., 2000; Paterson et al., 2003; Tuhkanen et al., 2004; Wernert et al., 2001). Other 
reports also demonstrated that in the process of tumor development, fibroblasts that have 
lost p53 activity were clonally selected, leading to a highly proliferative stroma (Hill et al., 
2005; Kiaris et al., 2005). In contrast, several genome-wide genetic analyses, including CGH 
and SNP arrays, were not able to detect any genetic alterations in the myofibroblasts 
isolated from various human cancers (Qiu et al., 2008; Walter et al., 2008). Other studies 
have suggested that epigenetic modifications within the genome of CAFs, such as DNA 
methylation, might be the reason (Hu et al., 2005; Jiang et al., 2008). Further studies are 
required to clarify these issues. 
2.1.4 Cancer stem/initiating cells 
Although cancer can originate from a single transformed cell, not all the cancer cells within 
a tumor are identical; in other words, cancer cells become heterogeneous during the somatic 
evolution process, reflected by distinct tumor regions with different histopathological 
characteristics and various degrees of tumor hallmark capacities. Moreover, mounting 
evidence indicates that tumor cells are also heterogeneous with regard to the capability to 
generate new tumors (Cho and Clarke, 2008; Lobo et al., 2007). Multiple studies showed that 
distinct subpopulations of cancer cells could be sorted from primary tumor samples based 
on their cell-surface antigen profiles. When different subpopulations of cells were injected 
into immune-deficient mice, only a subset of cells was able to propagate tumor growth, 
whereas other cells were unable to induce tumor regeneration (Lobo et al., 2007). This 
population of cancer cells has also been demonstrated to have the ability of self-renewal and 
differentiation, two hallmark characteristics of stem cells (Clarke et al., 2006). In addition, 
these cells also expresses some markers of normal stem cells (Al-Hajj et al., 2003); hence, 
these cells are termed as ‘cancer stem cells’ (CSCs; also referred as cancer initiating cells or 
tumorigenic cancer cells).  
CSCs were initially identified in leukemia (Bonnet and Dick, 1997; Lapidot et al., 1994) and 
later in solid tumors that include cancers of breast, brain, pancreas, head and neck, and 
colon (Al-Hajj et al., 2003; Dalerba et al., 2007; Li et al., 2007; O'Brien et al., 2007; Prince et al., 
2007; Ricci-Vitiani et al., 2007; Singh et al., 2004). Studies of leukemia stem cells suggest that, 
CSCs may arise from normal stem cells that acquire oncogenic mutations and undergo 
transformation (Fialkow, 1990; Lapidot et al., 1994; Lobo et al., 2007), or progenitor cells that 
gain the ability to self-renew through oncogenic transformation (Cozzio et al., 2003; Krivtsov 
et al., 2006; So et al., 2004). However, recent observations suggest that CSCs may also be 
derived from non-CSCs via the EMT process (Mani et al., 2008; Morel et al., 2008; Singh and 
Settleman, 2010), which plays an important role in morphogenesis and in promoting tumor 
cell motility and invasiveness (Hugo et al., 2007; Thiery, 2003). This model indicates that 
whereas CSCs can differentiate into non-CSCs; non-CSCs may also be reprogrammed and 
converted to CSCs, suggesting the existence of a dynamic interconversion between CSCs 
and non-CSCs that is controlled by the tumor microenvironment (Gupta et al., 2009). Such 
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plasticity of CSC state is absent in the conventional depiction of normal stem cells, and has 
changed the perception of CSCs biology. 
With regard to the frequency of CSC representation in tumors, there are conflicting results 
and ongoing controversies. Initially, CSCs were described to exist only as small 
subpopulations within tumors (Bonnet and Dick, 1997; Lapidot et al., 1994); moreover, since 
normal stem cells are usually rare, it was assumed that CSCs should also be rare. However, 
recent studies on human melanoma suggested that as many as a quarter of the cancer cells 
could be CSCs (Kelly et al., 2007; Quintana et al., 2008). This disparity on the frequency of 
CSCs reported were partially attributed to the experimental xenograft conditions in which 
the ability of human tumor cells to seed and grow in a mouse tissue may vary (Quintana et 
al., 2008). The plasticity of CSCs state may also in part account for the differences of CSCs 
representation. The balance of the interconversion between CSCs and non-CSCs could be 
shifted in one direction or another in response to microenvironmental signals (Santisteban et 
al., 2009; Till et al., 1964). It is suggested that the proportion of CSCs may differ between 
tumor types, dependent on stromal microenvironment and somatic mutations within 
tumors as well as tumor progression stage (Gupta et al., 2009). 
The existence of CSCs has attracted growing attention as CSCs may provide explanations 
for some puzzled clinical problems and imply novel cancer therapies (Clevers, 2011). CSCs 
have been shown to be more resistant to a variety of conventional radio/chemotherapies 
than non-CSCs (Chiu et al., 2010; Diehn et al., 2009; Li et al., 2008). Together with their 
ability to regenerate tumor and to colonize distant organs (Hermann et al., 2007), CSCs are 
proposed to be responsible for cancer recurrence following chemotherapy or radiation 
treatment, and for metastases that appear after surgical removal of a primary tumor. In 
addition, CSCs hypothesis implies that development of novel and more effective treatments 
that target the ‘seeds’ of the tumors might be a promising improvement of current therapy 
regimen. However, the plasticity of CSC phenotype implies that eliminating CSCs alone 
may not effectively cure tumors as they can be regenerated from non-CSCs, calling for dual 
targeting therapeutic regimens (Gupta et al., 2009). Moreover, there are controversies about 
the CSCs model and the experimental strategy employed to define the existence of CSCs. 
There are rising concerns about the xenograft assay, a typical experimental strategy in the 
CSC research, in which sorted cancer cells are xenotransplanted into immunodeficient mice. 
However, this method could induce cellular stress of the isolated cancer cells; moreover, the 
species barrier and the transplantation procedure within this approach could complicate the 
process of CSC identification (Clevers, 2011). It will be of importance to devise new 
strategies to detect functional presence of CSCs within a tumor.  
2.2 Angiogenesis 
The growth and progression of tumors rely on blood vessels to acquire oxygen and 
nutrients and to remove metabolic wastes (Papetti and Herman, 2002). During the early 
stage of tumor development, once the size of a tumor mass reaches the diffusion limit for 
oxygen and nutrients, it may stay in a dormancy state with a steady rate of cell proliferation 
and death (Fukumura and Jain, 2007). Some human tumors can remain dormant for a 
number of years. However, the steady state may be disturbed as oxygen-deprived tumor 
cells release angiogenic factors that trigger the ‘angiogenic switch’ and initiate new blood 
vessel formation from nearby existing ones (a process called angiogenesis) (Hanahan and 
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Folkman, 1996; Hanahan and Weinberg, 2000). Angiogenesis expands the tumor vascular 
network, enabling malignant cell proliferation and metastasis. Therefore, angiogenesis is a 
rate-limiting step in tumor development and progression.  
Angiogenesis is controlled by a fine-tuned equilibrium between angiogenic and angiostatic 
factors (Baeriswyl and Christofori, 2009; Bergers and Benjamin, 2003; Carmeliet and Jain, 
2000). Under normal physiological conditions, this balance is tightly regulated, so that the 
‘angiogenic switch’ is ‘on’ only when needed and otherwise remains ‘off’. Moreover, the 
newly formed vessels rapidly mature and become quiescent. By contrast, in tumors, the 
balance between positive and negative controls is disrupted due to an overproduction of 
pro-angiogenic factors. Consequently, new blood vessels are constantly produced in tumors. 
To date, more than two dozen pro-angiogenic factors and similar number of anti-angiogenic 
factors have been identified. Key pro-angiogenic molecules include vascular endothelial 
growth factor (VEGF), angiopoietin 1 (Ang1), platelet-derived growth factor (PDGF), 
placenta growth factor (PlGF), fibroblast growth factor 2 (FGF2), hepatocyte growth factor 
(HGF), among others (Adini et al., 2002; Papapetropoulos et al., 1999). Important angiogenic 
inhibitors include thrombospondin, angiostatin, endostatin, canstatin and tumstatin 
(Folkman, 2006; Kazerounian et al., 2008; Nyberg et al., 2005).  
VEGF signaling pathway is the most prominent and best characterized pro-angiogenic 
pathway (Ferrara et al., 2003). The VEGF family includes VEGF-A, B, C, D, and PlGF 
(Ferrara, 2002; Hicklin and Ellis, 2005). VEGF-A (also called VEGF) is the major regulator of 
tumor angiogenesis. There are several isoforms of VEGF-A, with 121, 165, 189 and 206 
amino acids, which are generated by alternative splicing (Houck et al., 1991; Tischer et al., 
1991). VEGF-A mainly binds to VEGF receptor 2 (VEGFR-2) and triggers various 
downstream signaling pathways to up-regulate genes that stimulate endothelial cell 
proliferation, migration and survival and increase vascular permeability (Dvorak, 2002; 
Shibuya and Claesson-Welsh, 2006). VEGF is expressed at elevated levels in most types of 
human cancer. This can be caused by diverse genetic and epigenetic factors (Kerbel and 
Folkman, 2002; Kerbel, 2008). Hypoxia, a hallmark of tumor microenvironment, is an 
important inducer of VEGF through the hypoxia-inducible factor (HIF) 1ǂ and 2ǂ (Semenza, 
2003). In addition, inflammatory cytokines, growth factors and chemokines can also induce 
VEGF expression. Other genetic causes include activation of oncogenes, such as mutant ras 
(Rak et al., 1995), or inactivation of tumor-suppressor genes, such as the von Hippel-Lindau 
(VHL) tumor suppressor (Patard et al., 2009).  
In addition to VEGF, there are other important signaling pathways that regulate 
angiogenesis. Endothelial cell-associated delta-like ligand (Dll) 4-notch signaling pathway 
acts as negative feedback mechanism of VEGF signaling to prevent excessive tumor 
angiogenesis (Lobov et al., 2007; Ridgway et al., 2006). HGF/c-Met signaling can induce 
VEGF and VEGFR expression and also promote angiogenic proliferation and survival (You 
and McDonald, 2008). FGF2 signaling can stimulate angiogenesis independent of VEGF 
(Beenken and Mohammadi, 2009). PDGF-B signaling is important for the recruitment of 
pericytes to nascent blood vessels and stabilization/maturation of the vasculature (Lindahl 
et al., 1997). The angiopoietins (Ang-1, 2), interacting with the Tie2 receptor, act in 
cooperation with VEGF to promote angiogenesis and stabilize and mature new vasculature 
(Augustin et al., 2009). PlGF, signaling through VEGFR1, is another growth factor that 
induces endothelial cell proliferation, migration and survival (Fischer et al., 2007). 
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Moreover, endothelial progenitor cells can also be recruited and contribute to the formation 
of new blood vessels. 
Due to the imbalanced expression of pro- and anti-angiogenic factors (Jain, 2005), tumor 
vasculature is often abnormal in architecture and function (Baluk et al., 2005; Fukumura and 
Jain, 2007). In contrast to the well-organized normal vascular tree, tumor blood vessels are 
highly variable in size, shape, and branching pattern. They are tortuous, dilated, irregularly 
shaped, and lack the normal hierarchy of arterioles, capillaries and venules. The structure of 
vessel wall is also defective, with large inter-endothelial junctions and loose perivascular 
cells attachment (McDonald and Choyke, 2003; Morikawa et al., 2002). Hence, tumor blood 
vessels are often leaky and hemorrhagic. Vascular permeability in tumor is generally higher 
than that in normal tissues, leading to increased interstitial fluid pressure. Also, blood flow 
in tumor vessels is irregular, slower, oscillating, and sometimes can even reverse the 
direction. Therefore, in spite of the production of excess blood vessels, the perfusion 
efficiency in tumor is still low. The aberrant tumor vasculature fails to meet the demand of 
growing tumor for nutrients and oxygen, as well as to adequately remove waste products. 
Chronically, the tumor microenvironment becomes hypoxic and acidic (Fukumura and Jain, 
2007). As stated in more detail in the following sections, hypoxia and acidosis are selection 
forces for cancer cell somatic evolution and also significantly affect radiation sensitivity and 
chemotherapeutic efficacy.  
As angiogenesis plays a critical role in tumor growth and progression, anti-angiogenesis 
therapy has been developed aiming to halt tumor growth by depriving cancer cells of the 
blood supply (Ferrara and Kerbel, 2005). Most of the angiogenesis inhibitors target the 
VEGF signaling pathway, including antibodies directly against VEGF and small molecules 
inhibiting its receptors. These anti-angiogenic agents have provided clinical benefits in 
patients with various types of cancers. Detailed discussion on anti-angiogenesis therapy is 
presented in the Section 3.1.  
2.3 Hypoxia 
The defective architecture and functionality of tumor blood vessels results in the occurrence 
of hypoxic regions in solid tumors (Fukumura and Jain, 2007; Gatenby and Gillies, 2004). 
Hypoxia is further exacerbated by the uncontrolled and rapid proliferation of tumor cells. 
These cancerous cells consume large amounts of oxygen and nutrients during their rapid 
divisions, further dictating the need for ample blood supply. As the oxygen diffusion limit is 
reached and the partial pressure of oxygen, pO2, drops towards zero, cells must adapt and 
rely upon alternative means to acquire energy in this hypoxic microenvironment (Bertout et 
al., 2008; Cairns et al., 2006; Fukumura and Jain, 2007; Gatenby and Gillies, 2004, 2007). A 
common adaptation strategy is the dependence upon glycolytic metabolism, coined the 
‘Warburg Effect’ (Gatenby and Gillies, 2004; Warburg, 1956). In cancer cells, a large portion 
of glucose is utilized through glycolysis, by which each glucose molecule is converted to 
two ATP and two lactic acid molecules. In contrast, normal cells obtain the majority of their 
ATP through oxidative phosphorylation, which results in the release of 36 ATP from one 
glucose molecule (Gatenby and Gillies, 2004; Vander Heiden et al., 2009). While less efficient 
in ATP production, glycolysis generates intermediate molecules as substrates for nucleotide, 
lipid and amino acid biosynthesis, which is crucial for rapidly dividing cancer cells (Vander 
Heiden et al., 2009). It is proposed that the acquisition of glycolytic metabolism offers a 
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selective advantage for cancerous cells, allowing them to adopt a more malignant phenotype 
(Gatenby and Gillies, 2004; Vander Heiden et al., 2009). 
In addition to the noted alteration in the mode of energy acquisition, hypoxia is also known 
to regulate gene expression of cells. To proliferate and thrive in a hypoxic environment, 
cancer cells must modulate numerous cellular pathways. For example, pathways that 
initiate the acquisition of a motile and invasive phenotype, such as the c-Met pathway 
(Eckerich et al., 2007), are activated to facilitate cancer cells to leave the primary, hypoxic 
tumor (Hanahan and Weinberg, 2011). It has been discovered that hypoxia-inducible factor 
1 (HIF-1) is a master regulator of many of the pathways that allow cancer cells to thrive in a 
hypoxic environment (Bertout et al., 2008; Semenza, 2007a, b). HIF-1 is reported to control 
the transcription of many genes, including those needed for maintaining cell viability, 
vascularization, glucose uptake, and metabolic reprogramming. HIFs are known to regulate 
pro-angiogenic and pro-glycolytic pathways. In animal models, HIF-1 overexpression has 
been associated with invasion, tumor growth and increased vascularization. Furthermore, 
HIF-1ǂ overexpression has been correlated with an increase in patient mortality (Rankin 
and Giaccia, 2008; Semenza, 2007a). HIF proteins have also recently been attributed to the 
survival and self-renewal of cancer stem cells (CSCs), which are involved in cancer cell 
propagation and the development of aggressive and metastatic phenotypes (Heddleston et 
al., 2010; Wang et al., 2011). The Notch and Oct4 pathways, responsible for maintaining the 
stem cell phenotype, have been reported to be under the regulatory control of HIF protein. 
Due to the immense involvement of HIF-1 in transcriptional regulation of genes that 
promote survival and progression of cancer cells in a hypoxic environment, it serves as a 
target of anti-cancer therapies (Semenza, 2007a; Tennant et al., 2010). 
Another effect of hypoxia lies in the resistance of cancer cells to chemotherapy and radiation 
treatment (Cairns et al., 2006; Gatenby and Gillies, 2004). Oxygen is known to increase the 
effectiveness of radiation therapy as it is a potent radiosensitizer. In turn, hypoxia can 
invoke a resistance of cancer cells to radiation and some forms of chemotherapy (Cairns et 
al., 2006). This hypoxia-induced resistance can be attributed, among many factors, to an 
inability in chemotherapy and radiation to induce cell cycle arrest, DNA breaks, and 
apoptosis (Wilson and Hay, 2011). Furthermore, hypoxia can up-regulate the expression of 
genes known to cause resistance to chemotherapeutics, such as multidrug resistance gene 
(MDR1), and downregulate the expression of apoptosis regulating genes (Bertout et al., 
2008). 
2.4 Acidosis 
As discussed above, cancer cells develop a modified form of energy metabolism in which 
glucose incorporated by the tumor is mainly converted into ATP and lactic acid through 
glycolysis even in the presence of oxygen (Gatenby and Gillies, 2004; Vander Heiden et al., 
2009; Warburg, 1956). In addition, it is believed this switch to a glycolytic phenotype, 
although inefficient in ATP production, is overall beneficial for rapidly dividing cancer cells 
(Cairns et al., 2011; Vander Heiden et al., 2009). However, the glycolytic metabolism directly 
results in the development of acidic interstitial pH in the tumor microenvironment, another 
stress that cancer cells must evolve to evade. 
Acidosis is another defining hallmark of the tumor microenvironment. Interstitial 
accumulation of hydrogen ions is due to the production of lactic acid from glycolysis and 
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other proton sources from, such as, ATP hydrolysis and carbonic acid (Gatenby and Gillies, 
2004; Helmlinger et al., 2002; Yamagata et al., 1998). Whereas the intracellular pH of cancer 
cells is kept neutral, an extracellular pH of 6.5-6.8 is often observed in the interstitial space of 
tumors (Griffiths et al., 2001). To maintain a relatively neutral intracellular pH, cancer cells 
utilize an array of acid-base transporters, such as sodium/hydrogen exchangers, vacuolar-
type H+-ATPases, and monocarboxylate transporters, to extrude the excess protons from 
cancer cells (Izumi et al., 2003; Webb et al., 2011).   
Just as the ability for tumor cells to adapt to a hypoxic microenvironment offers a distinct 
evolutionary advantage towards an aggressive phenotype, so does the ability for cancer 
cells to survive in an acidic microenvironment. Upon exposure to the low extracellular pH 
found in and around solid tumors, many of the normal, non-cancerous cells in the 
surrounding tissue undergo cell death, often attributed to p53-dependent pathways. Cancer 
cells that have evolved to be immune to this notable acidosis are often left highly invasive 
and aggressive (Gatenby and Gillies, 2004). Acidosis is also known to contribute towards 
tumor cell invasion through the release of proteolytic enzymes that degrade extracellular 
matrix. Hypoxia and acidosis have been reported to increase the secretion and activity of 
matrix metalloproteinases (MMPs) and other matrix-degrading enzymes (Bourguignon et 
al., 2004; Johnson et al., 2000; Ridgway et al., 2005). 
Acidosis also plays a role in the cytotoxic effectiveness of radiation and chemotherapy. 
Microenvironmental acidosis has been shown to invoke a resistance to radiation-induced 
apoptosis of cancer cells (Hunter et al., 2006). Acidic extracellular pH can also modulate the 
uptake of chemotherapeutic drugs, especially the weak acid and weak base drugs (Cairns et 
al., 2006; Gerweck et al., 2006). In the acidic tumor microenvironment, weak base drugs, 
such as doxorubicin, exist in a highly charged state. In turn, the uptake of these drugs across 
the plasma membrane is inhibited, thereby reducing the ability of the chemotherapeutic 
drugs to reach their cytotoxic target. In contrast, weak acid drugs, such as chlorambucil, 
exist in a non-charged state at acidic pH and, therefore, have increased cell permeability. 
2.5 Somatic evolution and cancer cell metastasis 
As normal cells are transformed to pre-malignant tumor cells and further towards 
malignant and metastatic tumors, the process of somatic evolution is actively used (Gatenby 
and Gillies, 2004). Cancer cells arise through gene mutations. Oncogenes with a dominant 
gain of function arise, while tumor suppressor genes become inactivated through a loss of 
function. As a result of somatic evolution, some of the traits that promote the cancerous 
phenotype include the evasion of apoptosis, limitless replicative potential, sustained 
angiogenesis, the ability for invasion and metastasis, and deregulated energy metabolism 
(Hanahan and Weinberg, 2011).  
Carcinogenesis and Darwinian dynamics draw an analogy as new phenotypes are generated 
through heritable genetic changes and subsequent selection for the fittest by the 
environment (Gatenby and Gillies, 2004, 2008). It has been proposed that hypoxia and 
acidosis both apply extreme constraints and act as selection forces for progressive tumor 
cells. Cancer cells that have gained immunity to these conditions, such as through the 
Warburg effect and other adaptations, display a distinct advantage over neighboring normal 
cells. Cancer cells that are able to thrive in the harsh environment are highly aggressive with 
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a resistant phenotype. Communication between tumor cells and the microenvironment is 
crucial for the cells to take advantage of the changes in the microenvironment and develop a 
malignant phenotype (Gatenby and Gillies, 2004; Lorusso and Ruegg, 2008). 
There are many mechanisms by which cancer cell somatic evolution is driven by the 
microenvironmental selection forces.  Primarily, various pathways crucial for cancer cell 
survival under the hypoxic and acidotic conditions are activated, such as those that promote 
a downregulation of apoptosis, a switch to glycolytic metabolism, and an upregulation of 
HIFs (Gatenby and Gillies, 2004; Heddleston et al., 2010; Vander Heiden et al., 2009; Wilson 
and Hay, 2011). Cancer cells resistant to acidosis and hypoxia often acquire p53 mutations. 
As p53 is important for apoptosis, cells that have a mutation in this gene exhibit an 
advantage as they are often immune to the cytotoxic microenvironment (Bertout et al., 2008). 
In addition, many tumor cells develop a very active sodium/hydrogen exchange system 
and other proton transport mechanisms, which facilitate the extrusion of excess protons 
(Izumi et al., 2003; Webb et al., 2011). The resulting cytoplasmic alkalinization is thought to 
be crucial for cell reproduction in the acidic environment. Therefore, the hallmarks of the 
tumor microenvironment, such as hypoxia and acidosis, actively function as selection forces 
to shape cancer cell phenotypes during the somatic evolution process (Gatenby and Gillies, 
2004; Webb et al., 2011). 
The ability to acquire a metastatic phenotype via somatic evolution is one of the most 
devastating properties of cancer cells, and is directly correlated with an increase in patient 
morbidity and mortality (Fidler, 2002; Steeg, 2006). Current cancer therapy approaches, such 
as surgery, radiation and chemotherapy, can be effective in controlling primary, localized 
tumor. However, these modes of treatment are severely limited in retarding the spread of 
cancer as they do little to impair metastasis. It is therefore evident that the development of 
novel means of combating tumor cell metastasis is crucial towards the eradication and 
control of this disease. 
The general steps of tumor metastasis involve the initial acquisition of motility and 
invasiveness, intravasation, transit in the blood or lymph, extravasation and finally arrest 
and growth at a new site (Fidler, 2002; Sahai, 2007; Steeg, 2006). The tumor 
microenvironment plays a large role in the ability of cancer cells to acquire a metastatic 
phenotype. As previously touched upon, two of the defining characteristics of the tumor 
microenvironment, hypoxia and acidosis, both actively select for more invasive and 
metastatic phenotypes (Chang et al., 2011; Gatenby et al., 2006; Gatenby and Gillies, 2004). It 
is also reported that inflammatory cells, fibroblasts and other stromal cells in the tumor 
microenvironment can contribute to the progression of a tumor towards a more malignant, 
metastatic phenotype (Joyce and Pollard, 2009; Lorusso and Ruegg, 2008).  
3. Tumor microenvironments as targets for cancer prevention and therapy 
Cellular components and molecular pathways associated with tumor microenvironments 
have been exploited as targets for cancer prevention and therapy. In fact, combination 
therapy targeting both cancer cells and other related cells and pathways, such as vascular 
cells and immune cells, can lead to more effective cancer treatment (Cairns et al., 2006; 
Ferrara and Kerbel, 2005; Luo et al., 2009). Therapeutic approaches modulating 
angiogenesis, inflammation, and hypoxia and acidosis pathways will be discussed  
below. 
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3.1 Anti-angiogenesis cancer therapy 
As described in the ‘angiogenesis’ session, tumors rely on angiogenesis to grow and 
disseminate. Therefore, it has been proposed that tumor growth can be inhibited by starving 
tumor cells through angiogenesis blockade (Folkman, 1971). Since VEGF is a major regulator 
of tumor angiogenesis, a number of agents targeting VEGF and its receptors have been 
developed and several have been approved by the Food and Drug Administration (FDA) for 
clinical applications. Among them, bevacizumab (Avastin, Genentech/Roche) is a 
humanized monoclonal antibody directly against VEGF (Ferrara et al., 2004; Presta et al., 
1997), and sunitinib (Sutent, Pfizer) and sorafenib (Nexavar, Bayer) are small molecule 
inhibitors that target multiple receptor tyrosine kinases (RTK), including VEGF receptors 
and PDGF receptors (Faivre et al., 2007; Kupsch et al., 2005; O'Farrell et al., 2003).  
Bevacizumab was approved by the FDA in 2004 on the basis of the survival benefit observed 
in a randomized phase III clinical trial, in which bevacizumab was administrated in 
combination with chemotherapy in patients with previously untreated metastatic colorectal 
cancer (Hurwitz et al., 2004). The clinical benefit of bevacizumab was also evaluated in other 
cancer types. The combination of bevacizumab with paclitaxel and carboplatin in patients 
with previously untreated nonsquamous non-small-cell lung cancer (NSCLC) improved 
primary endpoint of overall survival (OS) (Sandler et al., 2006). Moreover, the combined 
regimen of bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) were 
used to treat patients with previously treated metastatic colorectal cancers and prolonged 
progression-free survival (PFS) and OS (Giantonio et al., 2007). More recently, bevacizumab 
monotherapy was approved as a second-line therapy for glioblastoma multiforme (GBM) 
(Cohen et al., 2009). Some severe adverse effects of bevacizumab therapy, including 
gastrointestinal perforation and arterial thromboembolic complications, were observed in a 
small percentage of patients. Other side effects such as hypertension were also noticed 
(Eskens and Verweij, 2006; Verheul and Pinedo, 2007). Notably, in addition to the oncologic 
application, VEGF inhibitors are also used to treat the neovascular (wet) age-related macular 
degeneration (AMD), as VEGF has been demonstrated to be a mediator of ischemia-induced 
intraocular neovascularization (Chen et al., 1999; Ferrara et al., 2006; Gragoudas et al., 2004; 
Ng et al., 2006; Rosenfeld et al., 2006). 
Sunitinib and sorafenib are RTK inhibitors that inhibit the tyrosine phosphorylation of 
VEGFRs, PDGFRs, c-kit, and Flt-3 (Fabian et al., 2005; Smith et al., 2004). Sunitinib has been 
reported to prolong the time to progression in imatinib-refractory gastrointestinal stromal 
tumors (Goodman et al., 2007). Sunitinib was also approved by FDA for the treatment of 
metastatic renal cell carcinoma (Motzer et al., 2009; Motzer et al., 2006). Sorafenib has been 
shown to increase PFS in patients with metastatic renal cell carcinoma (Escudier et al., 2007). 
In addition, sorafenib was approved for treating hepatocellular carcinomas (Lang, 2008; 
Llovet et al., 2008). Pazopanib, another RTKI, was approved for the treatment of metastatic 
renal cell carcinoma (Sternberg et al., 2010). Moreover, there are other anti-angiogenic agents 
under investigation that target other signaling molecules involved in angiogenesis, such as 
antibodies against angiopoietin-2 and PlGF which have been shown to delay tumor growth 
in preclinical models (Fischer et al., 2007; Oliner et al., 2004). 
There were also some clinical trials with angiogenesis inhibitors that did not show 
significant clinical benefits. For instance, the combination of bevacizumab with gemcitabine 
didn’t show improved PFS or OS in patients with chemotherapy-naïve advanced pancreatic 
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cancer (Kindler et al., 2010). An earlier phase III trial of bevacizumab combined with 
gemcitabine and erlotinib for the same type of cancer increased PFS but didn’t improve 
primary endpoint of OS either (Van Cutsem et al., 2009). PFS, although an indicator of the 
efficacy of drugs, is a poor surrogate for OS, as PFS benefits are not always translated into 
OS benefits (Wilkerson and Fojo, 2009). The controversies about whether to keep the FDA’s 
approval of bevacizumab for metastatic breast cancer provide such an example. In 2008, 
bevacizumab was approved for treating breast cancer in combination with chemotherapy 
based on the results from the clinical trial E2100 (Miller et al., 2007). However, the study was 
only able to show an improved primary endpoint of PFS but not OS. Several subsequent 
clinical trials showed similar results (Miles et al., 2010; Robert et al., 2011b), which leads to 
recent recommended withdrawal of bevacizumab by FDA for metastatic breast cancer 
(Lenzer, 2011). 
Another major problem is that, even in those successful trials, the VEGF pathway inhibitors 
can only generate transitory clinical responses in most patients, with increased survival 
typically measured in months (Kerbel, 2008). Almost inevitably, temporary tumor shrinkage 
or stasis was followed by tumor relapse and progression. The modest responses to the anti-
angiogenic agents are partly due to the existence of resistance to the therapeutics (Bergers 
and Hanahan, 2008). Tumor cells and the stroma they reside in can adapt to the presence of 
angiogenesis inhibitors by acquiring means to evade angiogenesis blockade and sustain 
blood vessel and tumor growth. One important compensatory response is that, when the 
VEGF signaling pathway is inhibited, tumor may activate or up-regulate the expression of 
alternative pro-angiogenic factors, such as FGF2, PlGF, and PDGF pathways (Fernando et 
al., 2008); or in other cases, there are pre-existing redundant pro-angiogenic factors in the 
treated tumors (Bergers and Hanahan, 2008).  
Furthermore, a growing list of studies indicates that anti-angiogenic therapies may even 
lead to increased tumor invasiveness and metastasis (Ebos et al., 2009; Paez-Ribes et al., 
2009). Questions and concerns have been raised about the efficacy and safety of 
antiangiogenic agents in blocking different stages of tumor progression. Potential 
mechanisms of the increased metastasis may involve both tumor-dependent and host-
mediated responses (Ebos and Kerbel, 2011), such as increased expression of pro-metastatic 
proteins (Pennacchietti et al., 2003; Rofstad and Halsor, 2002), induction of tumor cell EMT 
(Higgins et al., 2007), and pericyte dysfunction (Bergers et al., 2003), among others. Perhaps 
the most prevailing proposition is that inhibition of angiogenesis could elicit an elevated 
level of tumor hypoxia, which selects for cancer cell populations that are able to grow in low 
oxygen environments and promote tumor invasion and metastasis (Rapisarda and Melillo, 
2009). Studies have demonstrated that hypoxia-induced mechanisms, such as the up-
regulation of c-Met and interleukin 8 (Pennacchietti et al., 2003; Rofstad and Halsor, 2002; 
Steeg, 2003), can promote cancer cells to disseminate to distant locations (Kienast et al., 
2010).  
As a breakthrough in cancer treatment, anti-angiogenesis therapies have provided survival 
benefits in certain cancer types and represent an important complement to the traditional 
chemotherapy strategies. However, there are ongoing challenges, such as the lack of lasting 
benefits for the majority of patients and an emerging, though still controversial, possibility 
that increased tumor invasion and metastasis might in some instances be induced by anti-
angiogenesis therapy. It will be of importance to understand the molecular basis of the 
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treatment limitations and to formulate improved strategies to overcome them. For example, 
combining anti-angiogenic therapy with anti-hypoxia agents or anti-metastatic agents might 
help overcome the metastatic phenotype induced by increased tumor hypoxia. 
3.2 Anti-inflammation in cancer chemoprevention and therapy 
Numerous studies show that inflammation plays an important role in cancer initiation, 
progression and metastasis. As described in the Section 2, infiltrating inflammatory cells 
such as macrophages, mast cells and neutrophils produce reactive oxygen and nitrogen 
species, growth factors, cytokines, chemokines, proteases and other bioactive factors in the 
tumor microenvironment (de Visser et al., 2006; Grivennikov et al., 2010). These bioactive 
factors can induce DNA mutagenesis, inhibit DNA repair enzymes, stimulate cancer cell 
proliferation, degrade extracellular matrix, and promote cancer cell invasion and metastasis. 
On the other hand, certain types of infiltrating immune cells, such as cytotoxic T cells and 
natural killer cells, can inhibit tumor progression. 
Chronic inflammation is closely associated with the development of some types of cancers. 
For instance, patients with inflammatory bowel disease or ulcerative colitis have an 
increased risk of developing colorectal cancer (Xie and Itzkowitz, 2008). Chronic Helicobacter 
pylori infection and ulcers are associated with gastric cancer and mucosa-associated 
lymphoid tissue lymphoma. Infection with hepatitis B virus increases the risk of developing 
liver cancer (Pages et al., 2010). Furthermore, epidemiological studies indicate that the use of 
aspirin and other nonsteroidal anti-inflammatory drugs is associated with a reduced cancer 
incidence. These widely documented observations provide the rationale to assess anti-
inflammatory agents in cancer chemoprevention and therapy (Kashfi, 2009). 
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been extensively evaluated for cancer 
chemoprevention. Aspirin (acetylsalicylic acid), a prototype NSAID, inhibits the 
cyclooxygenase (COX) enzymes and suppress the production of prostaglandins and 
thromboxanes. Aspirin exhibits chemopreventive effects on colon cancer in several 
randomized trials. A recent study performed a 20-year follow-up of 5 randomized trials to 
investigate the long-term effects of aspirin (75-300 mg daily) on colorectal cancer incidence 
and mortality (Rothwell et al., 2010). 391 of 14,033 patients (2.8%) had colorectal cancer 
during a median 18.3-year follow-up. Compared to the control group, the incidence of colon 
cancer, but not rectal cancer, was lower in the aspirin group. Furthermore, the benefit of 
aspirin increased with the duration of treatment. Allocation to aspirin treatment for 5 years 
or longer reduced the risk of proximal colon cancer by ~ 70% and also decreased the risk of 
rectal cancer. Moreover, a meta-analysis of 3 randomized controlled trials showed that, in 
more than 2,000 patients with previously resected colorectal adenomas, the aspirin groups 
(dose range from 81 to 325 mg per day), in comparison to the placebo groups, had a lower 
rate of tumor recurrence (Gao et al., 2009). In addition to colorectal cancer, a recent study 
showed that daily aspirin treatment for 5 years or longer reduced the mortality from several 
common types of solid cancers (Rothwell et al., 2011). However, not all studies supported 
the protective role of aspirin in cancer prevention. In the Woman’s Health Study, a low dose 
(100 mg) of aspirin every other day for an average 10 years of treatment did not reduce the 
risk of total, breast, colorectal, and other cancers (Cook et al., 2005). The major adverse 
effects of aspirin treatment are gastrointestinal bleeding and ulceration.            
In addition to aspirin, COX-2 specific inhibitors have been tested as cancer chemopreventive 
agents. There are two COX genes in the cell: COX-1 is constitutively expressed in many 
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tissues and COX-2 is induced upon inflammation and other stimuli (Botting, 2010). Earlier 
clinical studies showed that the COX-2 inhibitor, celecoxib (400 mg twice per day for 6 
month), resulted in approximately 30% reduction in polyp number and size in familial 
adenomatous polyposis (FAP) patients (Steinbach et al., 2000). However, studies found that 
prolonged use of COX-2 inhibitors increased the risk of cardiovascular events in a dose-
related manner (Baron et al., 2008; Solomon et al., 2005; Solomon et al., 2006). These findings 
led to the discontinuation of the clinical trials and the withdrawal of the drugs from the 
market. Clearly, drugs with improved safety profiles are required for the long-term use in 
cancer chemoprevention. In this respect, the “old” NSAID, aspirin, has been widely used to 
prevent cardiovascular diseases and, therefore, has a favorable cardiovascular profile.        
Inflammatory chemokines and their receptors have also been exploited as targets for cancer 
therapy. Chemokines are a family of chemotactic cytokines that bind to cognate G protein-
coupled receptors. Forty-seven chemokine members have been identified and are divided 
into 4 subfamilies: the CC subfamily, the CXC subfamily, the CX3C subfamily, and the XC 
subfamily. The chemokine receptors are comprised of the CCR subfamily, the CXCR 
subfamily, CX3CR1, and XCR1 (Lazennec and Richmond, 2010). In the tumor 
microenvironment, various chemokines are produced by cancer cells, inflammatory cells, 
fibroblasts, and endothelial cells. Chemokines can stimulate cancer cell growth and 
metastasis, recruit inflammatory cells, and promote tumor angiogenesis. 
Stromal cell-derived factor-1 (SDF-1, also named CXCL12) and its receptor CXCR4 play 
important roles in the mobilization and homing of hematopoietic stem cells and the 
metastasis of cancer cells. AMD3100 (plerixafor), developed by Genzyme, is a small 
molecule that antagonizes the binding of CXCL12 to its receptor CXCR4, and was recently 
approved by FDA for stem cell mobilization in non-Hodgkin’s lymphoma and multiple 
myeloma patients (Pusic and DiPersio, 2010). Clinical trials demonstrated that AMD3100 
(plerixafor), together with G-CSF, significantly increased the mobilization of hematopoietic 
stem cells for autologous stem cell transplantation in patients with multiple myeloma and 
non-Hodgkin’s lymphoma (DiPersio et al., 2009a; DiPersio et al., 2009b). AMD3100 
(plerixafor) can also be used as a chemosensitizing agent. Studies showed that AMD3100 
(plerixafor) impeded the interaction between leukemia cells and the bone marrow 
microenvironment, mobilized cancer cells into peripheral blood, and increased the 
sensitivity of multiple myeloma cells and acute myeloid leukemia cells to chemotherapeutic 
drugs (Azab et al., 2009; Nervi et al., 2009). Furthermore, CXCL12/CXCR4 inhibitors have 
therapeutic effects on other non-hematological cancers. In pre-clinical models, blockade of 
CXCR4 has been shown to inhibit the migration and metastasis of melanoma cells, oral 
squamous cell carcinoma cells, and gastric cancer cells (Kim et al., 2010; Uchida et al., 2011; 
Zhao et al., 2011). CXCR4 inhibitors could also chemosensitize and suppress the growth of 
pancreatic and ovarian cancer cells (Righi et al., 2011; Singh et al., 2010). Besides 
CXCL12/CXCR4, inhibitors for other chemokines/receptors, such as CCL2 and CCR4, are 
also undergoing clinical development for the treatment of leukemia and solid tumors 
(Lazennec and Richmond, 2010).                
3.3 Molecular targeting of hypoxia pathways 
As described in the Section 2, hypoxia inhibits the tumor killing effects of radiation and also 
regulates cancer cell apoptosis, invasiveness and metabolism (Cairns et al., 2006; Gatenby 
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and Gillies, 2004). Hypoxia-inducible factors (HIFs) are master regulators of cell hypoxia 
responses and control the expression of numerous genes involved in angiogenesis, 
glycolytic metabolism, glucose transport, erythropoiesis, and other processes (Semenza, 
2007b). Increased expression of HIFs is correlated with a worse prognosis in many types of 
cancers. Thus, HIFs have been proposed as a potential target for cancer therapy. Inhibitors 
of the HIF pathway have been developed and tested in preclinical models and/or clinical 
trials (Semenza, 2007a).  
PX-478, a HIF-1ǂ inhibitor, showed remarkable antitumor activity in human cancer 
xenograft models (Welsh et al., 2004), and also enhanced radiosensitivity of human 
pancreatic cancer xenografts (Schwartz et al., 2009). It has been shown that the degradation 
of HIF-1ǂ can be induced through inhibiting the chaperone protein HSP90 (Isaacs et al., 
2002). The HSP90 inhibitor, 17-AAG (Tanaspimycin), exhibited anti-tumor activities in 
multiple cancer cell models. A recent phase II clinical trial showed that 17-AAG 
(Tanaspimycin) plus trastuzumab had significant anti-cancer activity in HER2+ breast cancer 
patients previously progressing on trastuzumab (Modi et al., 2011). It should, however, be 
noted that HIF-1ǂ degradation is only one of the effects of HSP90 inhibitors as HSP90 is 
required for preventing the degradation of many other proteins.     
As a response and adaptation to hypoxia in the tumor microenvironment, cancer cells rely 
substantially on glycolysis for ATP production. It was discovered by Otto Warburg decades 
ago that cancer cells preferentially utilize glycolytic metabolism even under aerobic 
conditions (known as ‘Warburg effect’) (Warburg, 1956). Since glycolysis only generates 2 
ATP molecules per glucose, tumor cells evolve a compensatory mechanism by up-regulating 
the level of glucose transporters and significantly increasing glucose uptake.  
Genes involved in glycolytic metabolism have been proposed as potential cancer therapeutic 
targets (Tennant et al., 2010). Studies demonstrate that HIFs directly activate the 
transcription of glucose transporters (e.g. GLUT1) and several key glycolytic enzymes 
(Semenza, 2007b). Some oncogenes and tumor suppressors, such as Myc, PI3K, p53 and 
PTEN, can also regulate the expression of genes important for glycolysis and cell 
metabolism (Dang et al., 2009; Tennant et al., 2010). A recent chemical screening identified a 
compound, STF-31, which could inhibit the glucose transporter 1 (GLUT1) and the Warburg 
effect, induce cell death of renal cell carcinoma and inhibit the growth of tumor xenografts 
(Chan et al., 2011). Agents have also been developed to target the enzymes in the glycolysis 
pathway. One such agent is the hexokinase inhibitor, 2-deoxyglucose, which has been 
shown to have anti-tumor activities in multiple cancer cell models (Loar et al., 2010; Zhang 
and Aft, 2009). Other potential anti-cancer targets in the glycolysis cascade includes 
pyruvate kinase, the tumor-specific pyruvate kinase M2 (PKM2) isoform, pyruvate 
dehydrogenase kinase 1 (PDK1), among others (Tennant et al., 2010; Vander Heiden et al., 
2009). Inhibitors of these enzymes, such as TLN-232 and dichloroacetate (DCA), are being 
evaluated in clinical trials. A recent study showed that DCA had anti-tumor activities in 
glioblastoma patients (Michelakis et al., 2010).  
Furthermore, major regulators of metabolic pathways, such as mTOR (mammalian target of 
rapamycin) and AMPK (AMP-activated protein kinase), have been employed as important 
targets for cancer therapy. In particular, the mTOR inhibitors, everolimus and temsirolimus, 
have been approved by FDA for the treatment of advanced renal cell carcinoma with clinical 
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benefits in prolonging progression free survival and overall survival (Kwitkowski et al., 
2010; Motzer et al., 2008). Moreover, epidemiological studies indicated that the cancer 
incidence is lower in diabetic patients treated with the AMPK agonist metformin (Bo et al., 
2011). In a short-term prospective clinical trial, metformin treatment reduced colorectal 
aberrant crypt foci in non-diabetic patients (Hosono et al., 2010). These results indicate that 
metformin may be a useful agent for cancer prevention and therapy (Gonzalez-Angulo and 
Meric-Bernstam, 2010; Li, 2011).   
In addition to targeting hypoxia-related molecular pathways, hypoxia itself can be utilized 
for cancer therapy. Bioreductive prodrugs, which are activated in hypoxic environments, 
have been evaluated as potential anti-cancer agents to selectively kill hypoxic tumor cells. 
For instance, apaziquone (EO9), a bioreductive prodrug, was used through instillation to 
treat bladder cancer and significantly reduced the rate of tumor recurrence in the clinical 
trials (Hendricksen et al., 2009; Jain et al., 2009).   
Hypoxia as a hallmark of the tumor microenvironment has also been exploited to develop 
imaging approaches for cancer diagnosis. A family of nitroimidazole derivatives has been 
used as chemical tracers to detect hypoxia in tissues. A PET probe, 18F-fluoromisonidazole 
(FMISO), has been applied to detect hypoxic regions in solid tumors and to assess the 
change of tumor hypoxia status in response to therapy such as anti-angiogenesis treatment 
(Szeto et al., 2009; Valable et al., 2011). In addition, the up-regulation of hypoxia-responsive 
glucose transporters in tumor cells has been utilized for [18F] fluorodeoxyglucose positron 
emission tomography (FDG-PET). As the uptake of glucose is substantially increased in 
cancer cells, the radioactive [18F] fluorodeoxyglucose tracer is preferentially accumulated in 
the tumor and can be detected by positron emission tomography (Buerkle and Weber, 2008). 
FDG-PET has been widely used in the clinic to detect tumors and metastases and assess the 
response of tumors to therapeutics.  
3.4 Molecular targeting of acidosis-related pathways 
In addition to hypoxia, extracellular acidosis is another major hallmark of the tumor 
microenvironment. To avoid the harmful accumulation of protons and decrease of 
intracellular pH (pHi), cancer cells must use the cellular transporter system to expel excess 
acids from the cells. Carbonic anhydrases (CA), monocarboxylate transporters (MCT), 
vacuolar-type H+-ATPase proton pump (V-ATPase), and sodium/hydrogen exchangers 
(NHE) play important roles in cellular pH regulation (Izumi et al., 2003; Swietach et al., 
2010; Webb et al., 2011). Furthermore, recent studies have shown that a family of proton-
sensing G protein-coupled receptors regulates the behavior of tumor cells, immune cells, 
and blood vessels (Ludwig et al., 2003; Mogi et al., 2009; Yang et al., 2007). Targeting these 
pH regulators may be utilized to kill cancer cells or to augment the effects of other anti-
cancer agents. 
Carbonic anhydrase (CA) enzymes catalyze the reversible reaction between carbon dioxide 
and bicarbonate: CO2 + H2O ↔ HCO3- + H+, and facilitate the transport of CO2 and H+ ions 
for pH regulation (Swietach et al., 2010). There are 15 CA isoforms, I to XV, in mammalian 
cells, located in the cytosol, mitochondrion, extracellular plasma membrane, or secreted. In 
particular, the isoform IX (CAIX) has been extensively studied in cancer biology (Swietach et 
al., 2010). The expression of CAIX is strongly induced by hypoxia and regulated by HIF-1. 
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CAIX has been used as an endogenous marker to delineate hypoxic regions in solid tumors 
and is a prognostic marker of aggressive cancers. Inhibition of CAIX has been shown to 
suppress tumor growth in xenograft models (Chiche et al., 2009). CAIX small molecule 
inhibitors and antibodies have been developed and evaluated as potential anti-cancer 
therapeutics. A CAIX monoclonal antibody exhibited anti-tumor activities in the mouse 
xenograft model of colorectal cancer (Zatovicova et al., 2010). Moreover, CAIX inhibitors 
were shown to increase the therapeutic effects of tumor radiation (Dubois et al., 2011). 
Monocarboxylate transporters (MCT) facilitate the efflux of lactate and protons from cells. 
The up-regulation of MCTs has been observed in a variety of tumors such as breast, 
colorectal, ovarian, prostate, and central nervous system carcinomas, and associated with 
cancer progression and poor prognosis in some instances (Fang et al., 2006; Froberg et al., 
2001; Pertega-Gomes et al., 2011; Pinheiro et al., 2010; Pinheiro et al., 2008). MCT1 and MCT4 
were related to the invasiveness of human lung cancer cells and drug resistance of ovarian 
cancer cells (Chen et al., 2010; Izumi et al., 2011). Inhibition of MCT1 could retard the 
growth of cancer cells in culture and animal models (Fang et al., 2006; Sonveaux et al., 2008). 
MCTs may, therefore, represent potential targets for cancer treatment.   
Vacuolar-type H+-ATPases (V-ATPases) are multi-subunit, complex enzymes that transport 
protons from the cytoplasm to vacuolar lumens or to extracellular space (Izumi et al., 2003). 
These proton pumps are important for maintaining intracellular and extracellular pH 
homeostasis. V-ATPases overexpression has been detected in many types of tumors such as 
oral squamous cell cancer and melanoma (Nishisho et al., 2011; Perez-Sayans et al., 2010). 
Studies showed that V-ATPases increased cancer metastasis and drug resistance (Nishisho 
et al., 2011; You et al., 2009). Inhibition of V-ATPases by small molecule inhibitors or small 
interfering RNA suppressed tumor growth and metastasis, induced tumor cell apoptosis, 
and overcame chemoresistance in several cancer models (De Milito et al., 2007; Lu et al., 
2005; Nishisho et al., 2011; You et al., 2009).    
Sodium/hydrogen exchangers (NHE) regulate the pH homeostasis of cells by extruding 
intracellular H+ in exchange of extracellular Na+ at a 1:1 ratio. Nine NHE isoforms have been 
identified in mammalian cells (De Vito, 2006). NHEs were found to regulate cytoskeletal 
structures and tumor cell migration and invasion (Paradiso et al., 2004). Treatment with 
NHE1 inhibitors sensitized the paclitaxel-induced apoptosis of human breast cancer cells 
(Reshkin et al., 2003). Moreover, increased activity of NHE was observed in doxorubicin-
resistant human colon cancer cells and the treatment with the NHE inhibitor 5-(N-ethyl-N-
isopropyl)-amiloride (EIPA) sensitized the resistant cells to doxorubicin (Miraglia et al., 
2005). Inhibition of NHEs has also been shown to reduce the proliferation and VEGF 
production of leukemia cells (He et al., 2007; Turturro et al., 2007).       
Proton-sensing G protein-coupled receptors (GPCRs), including GPR4, TDAG8 (GPR65), 
OGR1 (GPR68), and G2A (GPR132), can be activated by acidic extracellular pH to transduce 
multiple downstream signaling pathways such as the Gs/cAMP, Gq/phospholipase C/Ca2+, 
and G13/Rho pathways (Ludwig et al., 2003; Murakami et al., 2004; Radu et al., 2005; Tobo et 
al., 2007; Wang et al., 2004; Yang et al., 2007). Different from the proton transporters, the 
proton-sensing GPCRs do not directly transport protons but, instead, perceive acidic 
extracellular pH to trigger signal transduction. Potential roles of the proton-sensing GPCRs 
in cancer biology have been emerging, with differential roles for each family member in a 
cell context-dependent manner. Activation of GPR4 by acidic pH has been shown to inhibit 
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tumor cell migration, invasion and metastasis and suppress microvascular outgrowth 
(Castellone et al., 2011; Yang et al., 2007). Overexpression of OGR1 also inhibited the 
migration and metastasis of prostate cancer cells and the effects were attributed to the 
constitutive activity of the receptor but not pH sensing function (Singh et al., 2007). 
Overexpression of TDAG8, however, enhanced the development of lung cancer cells (Ihara 
et al., 2010). TDAG8, as well as GPR4, exhibited transforming activities when ectopically 
overexpressed in immortalized cell lines (Sin et al., 2004). Furthermore, the proton-sensing 
GPCRs have been shown to regulate immune cell function and inflammatory responses 
(Ichimonji et al., 2010; Mogi et al., 2009; Onozawa et al., 2011). These observations suggest 
that the proton-sensing GPCRs may represent novel targets for cancer treatment, 
inflammation inhibition, and chemoprevention.  
Taken together, the acid-base transporters and proton-sensing receptors described above are 
important for cancer cells to sense and adapt to the acidic tumor microenvironment. Further 
research is warranted to validate these pH regulators as potential targets for cancer therapy 
and chemoprevention. Moreover, acidity itself in the tumor microenvironment can also be 
exploited for cancer detection and treatment. Recent studies showed that a technology using 
the pH low insertion peptide (pHLIP), a peptide that forms ǂ-helix at acidic pH and inserts 
across cell membrane, could be applied to image prostate cancer xenografts in mice by 
positron emission tomography (Vavere et al., 2009). Acidity in the tumor microenvironment 
may also be utilized to design pro-drugs that are activated or become more potent at acidic 
pH to differentially kill cancer cells.   
4. Concluding remarks 
Cancer cells do not exist in isolation; instead, they closely interact with blood vessels, 
inflammatory cells, and fibroblasts in a unique tumor microenvironment characterized by 
hypoxia and acidosis. The interaction between cancer cells and the tumor microenvironment 
plays a pivotal role in cancer progression and somatic evolution, which follows very similar 
principles of Darwinian selection. It is increasingly recognized that in addition to killing 
cancer cells, targeting the components of the tumor microenvironment can help develop 
more effective approaches for cancer prevention and therapy. For instance, anti-
angiogenesis therapy, combined with conventional chemotherapy, has shown significant 
clinical benefits in multiple cancer types (Ferrara and Kerbel, 2005; Kerbel, 2008). 
Furthermore, a number of agents targeting inflammation, cancer cell metabolism, and 
hypoxia and acidosis pathways have been developed and added to the arsenal for cancer 
treatment, detection, diagnosis, prognosis and chemoprevention.  
While significant progress has been made to understand the tumor-microenvironment 
interaction, considerable knowledge gaps still remain. This aspect is exemplified by the 
lessons learned from anti-angiogenesis therapy. Whereas angiogenesis inhibitors have 
offered therapeutic benefits in cancer patients, some unexpected adverse effects deserve a 
close attention. In certain experimental settings, anti-angiogenesis therapy has been shown 
to promote tumor invasion and metastasis (De Bock et al., 2011; Ebos and Kerbel, 2011; Ebos 
et al., 2009). The underlying cause is largely attributed to the anti-angiogenesis therapy-
induced hypoxia, which is known to stimulate cancer cell metastasis. These observations 
illustrate that cancer cells constantly evolve and adapt to the changing tumor 
microenvironment during therapeutic interventions and/or tumor development. In 
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addition to hypoxia, other microenvironmental factors, such as acidosis and low nutrients, 
are also important selection forces that have a significant impact on cancer cell somatic 
evolution. The experience of anti-angiogenesis therapy once again underscores the fact that 
tumors comprise not just cancer cells and these cancer cells are continuously evolving. It is 
necessary to target multiple cell components and molecular pathways (both cancer cell-
intrinsic and microenvironment-related) in order to devise more effective strategies for the 
treatment and prevention of cancer. 
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